Circio invited to present circVec circular RNA technology at upcoming international RNA therapeutics conferences
Oslo, Norway 26 June 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr. Victor Levitsky have been invited to speak at two upcoming biopharma industry RNA conferences in Frankfurt, Germany, and San Diego, USA.
The European mRNA conference 2024
Title: Is circular RNA surpassing mRNA as the RNA format for the future?
Time & place: 26 June 2024, 11:00 CEST, Frankfurt, Germany
Presenter: Dr. Victor Levitsky, CSO
Title: Deploying circular RNA expression to boost gene therapy – AAV and beyond
Time & place: 4 September 2024, 15:05 PST, San Diego, USA
Presenter: Dr. Erik Digman Wiklund, CEO
These invitations to present at important RNA industry conferences place Circio along other leading RNA companies, such as Moderna, Biontech and oRNA Therapeutics. The presentations will provide an important forum to highlight the advantages and potential of circular RNA and reinforce Circio´s position as discoverers and leaders in this rapidly emerging field.
The presentations will be made available on Circio´s webpage on the respective dates.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA gene therapies and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.